Cargando…
Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors
IMPORTANCE: Immunotherapy using immune checkpoint inhibitors has been remarkably effective for treating multiple cancer types, and the gut microbiome is a possible factor affecting immune checkpoint inhibitor efficacy. However, the association between the gut microbiome and immune status of the tumo...
Autores principales: | Nomura, Motoo, Nagatomo, Ryosuke, Doi, Keitaro, Shimizu, Juko, Baba, Kiichiro, Saito, Tomoki, Matsumoto, Shigemi, Inoue, Koichi, Muto, Manabu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163404/ https://www.ncbi.nlm.nih.gov/pubmed/32297948 http://dx.doi.org/10.1001/jamanetworkopen.2020.2895 |
Ejemplares similares
-
Femoral placement of a totally implantable venous access port with spontaneous catheter fracture: case report
por: Kondo, Tomohiro, et al.
Publicado: (2020) -
Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy
por: Nomura, Motoo, et al.
Publicado: (2023) -
Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016) -
Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma
por: Fujii, Yosuke, et al.
Publicado: (2017) -
Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)